OPHIOMICS - INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA

Their core work

Ophiomics is a Portuguese biotech SME specializing in molecular diagnostics applied to organ transplantation medicine. Their core product, HepatoPredict, is a clinical decision support tool that uses molecular signatures — likely genomic or transcriptomic biomarkers — to help clinicians assess liver grafts and predict transplant outcomes. They progressed from a feasibility study (SME Instrument Phase 1, 2018) to a full commercial development project (Phase 2, 2020–2022), indicating a focused product company rather than a broad research services provider. Their work sits at the intersection of omics-based diagnostics and clinical decision-making in hepatology and transplant surgery.

What they specialise in

How they've shifted over time

Ophiomics has not pivoted — they have drilled deeper. Their entire H2020 trajectory is a single product taken from proof-of-concept to commercialization-ready stage. The 2018 Phase 1 project established the scientific and commercial feasibility of HepatoPredict; the 2020 Phase 2 project funded the full clinical validation and market development. There is no visible diversification into other disease areas or technology types within the available data, which suggests either strong focus or that earlier-stage work predates their EU funding history.

Ophiomics is on a commercialization trajectory for a single, highly focused product — any future collaboration would likely center on clinical validation partnerships, hospital network access, or expansion of HepatoPredict into adjacent transplant indications (kidney, lung).

How they like to work

Ophiomics has operated exclusively as a solo coordinator through the SME Instrument, a funding scheme specifically designed for single-company projects — so the absence of consortium partners is structural, not a reflection of isolation. This tells us they are self-sufficient at the R&D and product development level and do not rely on academic or industrial partners to execute their core work. For future Horizon Europe or EIC Accelerator projects, they would likely continue in a lead or solo role rather than as a consortium participant.

Ophiomics has no recorded consortium partners in their H2020 history, which is expected for SME Instrument projects that fund a single company. Their external network — clinical trial sites, hospital partners, and advisors — exists but is not captured in CORDIS data.

What sets them apart

Ophiomics occupies a rare niche: molecular diagnostics purpose-built for organ transplantation decisions, a field where most diagnostics players focus on oncology or infectious disease. Their HepatoPredict product targets an unmet clinical need — liver graft assessment remains heavily experience-dependent — giving them a defensible position in a low-competition diagnostic segment. For a consortium builder, they bring both the scientific IP and the clinical translation experience needed to bridge research and hospital adoption.

Highlights from their portfolio

• HepatoPredict (SME-2b)
  The largest project (€757k) represents the full commercial development phase of their flagship product, making it the most strategically significant project in their portfolio.
• HepatoPredict (SME-1)
  The Phase 1 feasibility grant (€50k) validated the scientific and business case that unlocked the larger Phase 2 award — a successful two-stage EU funding progression that few SMEs complete.